Outlook Therapeutics (OTLK) Stock: Buy, Sell, or Hold?
OTLK - Outlook Therapeutics, Inc. Common Stock
$0.64
-0.02 (-3.35%)
▼
5d:
-4.29%
30d:
-28.23%
90d:
-47.71%
BUY
HIGH Confidence
Analysis Updated: Sep 14, 2026 12:00 AM ET
Earnings: Aug 14, 2026
0d
Get Alerted When OTLK Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: OTLK shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
✅ BUY SIGNAL: OTLK shows strong fundamentals and good volume confirmation. Solid entry point despite slightly low pricing.
In-depth Analysis How we analyze
Valuation Analysis: OTLK is currently trading at $0.64, which is considered slightly low relative to its 30-day fair value range of $0.57 to $0.91.
Technical Outlook: Technically, OTLK is in a uptrend. Immediate support is located at $0.60, while resistance sits at $0.70. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: OTLK scores 94/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $5.03 (+687.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, OTLK is in a uptrend. Immediate support is located at $0.60, while resistance sits at $0.70. Short-term momentum is weak, with the stock down 3.3% recently.
Market Sentiment: OTLK scores 94/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $5.03 (+687.7%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
SLIGHTLY LOW
Historical Trading Range
$0.57 -
$0.91
Company Quality Score
68/100
(BUY)
Volume Confirmation
HIGH
Confidence Score
89.5%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (94/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-3.3%)
- BULLISH: Trading 687.7% below Wall St target ($5.03)
- BULLISH: Bottoming setup score 94/100 — corrected, stabilizing, and turning up
Trading Range Analysis
30-Day Trading Range
$0.57 -
$0.91
Current vs Trading Range
SLIGHTLY LOW
Support & Resistance Levels
Support Level
$0.60
Resistance Level
$0.70
Current Trend
Uptrend
Technical data as of
Sep 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-5.32
Wall Street Target
$5.03
(+687.7%)
Revenue Growth (YoY)
-99.4%
Share & Embed Analysis
Last updated: September 15, 2026 3:59 AM ET
Data refreshes hourly during market hours. Next update: 4:59 AM
Data refreshes hourly during market hours. Next update: 4:59 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is OTLK showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 56 HOLD |
|
AXSM
Axsome Therapeutics Inc |
STRONG BUY
19 analysts |
$285 | 49 HOLD |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$36 | 48 HOLD |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$34 | 53 HOLD |
|
BBIO
BridgeBio Pharma Inc |
STRONG BUY
19 analysts |
$109 | 52 HOLD |
